Madrigal Pharmaceuticals, Inc. (MDGL)
InfravaloradaFundamental
28
Precio
$503.96
Capitalización Bursátil
$11.64B
Parte 1 · Cuánto vale la empresa
Resumen
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance y Liquidez
Ingresos
$1.28B
Últimos 12 meses (hasta 30/6/2026)
Beneficio Neto
$-325M
Últimos 12 meses (hasta 30/6/2026)
Flujo de Caja Libre
$-190M
Patrimonio Neto Total
$603M
Pasivo Total
$657M
Ratio de Liquidez
3.20
Cobertura de Intereses
10.24
Deuda/EBITDA
-
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$682.11
Precio Actual
$503.96
Margen de Seguridad
+26.1%
Rango de Valor Justo
$648.01 - $716.22
Dispersión entre los métodos de valoración utilizados, no un intervalo de confianza calibrado estadísticamente.
Métodos de Estimación
Métricas de Valoración
Ratio P/E
-
ROE
-47.8%
Ratio P/B
22.23
P/FCF
-
Margen Bruto
-
ROIC
-29.3%
Radar de Rentabilidad
Creación de Valor (Ventaja Competitiva)
ROIC
-29.3%
WACC
7.9%
ROIC − WACC
-37.2 pp
El ROIC está por debajo del coste del capital: la empresa destruye valor por cada dólar invertido.
Criterios de Análisis Fundamental
Superado (7)
- Price CAGR 42.47%
- Debt/Equity ratio
- Current Ratio
- Interest Coverage
- Low reliance on intangibles
- Analyst Consensus 92% Buy
- Net Margin Trend -25.3% vs -54.7%
Fallido (11)
- EPS shows upward trend
- ROIC -29.3%
- P/B Ratio 22.23
- Operating Margin -25.1%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -56.6%
- Earnings Surprise avg -90.7%
- Share Dilution 5.5%
- Piotroski F-Score 3/9
No disponible (9)
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Debt/EBITDA
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Preocupaciones financieras graves
Calidad de los Beneficios
Baja calidad: investigue la contabilidad
Dilución de Acciones
Emitiendo nuevas acciones, diluyendo la participación
Participaciones institucionales
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Mr. William J. Sibold | CEO, President & Director | 59 |
| Dr. Rebecca A. Taub M.D. | Founder, Senior Scientific & Medical Advisor and Director | 73 |
| Ms. Mardi C. Dier | Executive VP & CFO | 61 |
| Ms. Shannon Kelley | Executive VP, Chief Legal Officer & Corporate Secretary | 50 |
| Ms. Carole Huntsman | Executive VP & Chief Commercial Officer | 60 |
| Dr. David Soergel M.D. | Executive VP & Chief Medical Officer | 57 |
| Mr. Mark Underwood | Executive Vice President of Business Planning & Operations | - |
| Ms. Rita Thakkar | Senior VP & Chief Accounting Officer | 51 |
| Mr. Ronald Filippo | Executive VP & Chief Information Officer | - |
| Ms. Tina E. Ventura | Chief Investor Relations Officer | - |
Riesgo de Auditoría
2
Riesgo del Consejo
3
Riesgo de Compensación
5
Riesgo de Derechos del Accionista
8
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Documentos
- Ver documento
Informe anual (10-K)
Un resumen anual del negocio, los resultados financieros y los riesgos de la empresa.
Presentado el 2026-02-19
- Ver documento
Informe trimestral (10-Q)
Una actualización del desempeño financiero de los últimos tres meses.
Presentado el 2026-07-30
- Ver documento
Informe de hecho relevante (8-K)
Un aviso sobre un hecho relevante, como un cambio de dirección o un anuncio importante.
Presentado el 2026-08-12
via SEC EDGAR
Historial de Resultados
via SEC EDGAR
Latest News
Recent headlines for MDGL, sourced from Markets Gazette.
- 5/6/2026NEUTRALFull Transcript: Madrigal Pharmaceuticals Q1 2026 Earnings Call
Madrigal Pharmaceuticals Inc. held its Q1 2026 earnings call on May 6, 2026. While the transcript is available, the provided snippet does not contain specific financial results, forward-looking statements, or significant operational updates that would directly impact the company's stock valuation. Investors seeking to assess the company's performance and outlook should refer to the full earnings report and call transcript for detailed financial figures, management commentary on key business drivers, and any guidance provided for future periods. Without this detailed information, a definitive market impact cannot be determined.
- 3/17/2026POSITIVEThis Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally
Madrigal Pharmaceuticals, a clinical-stage biotech focused on NASH, obesity, and metabolic diseases, has seen its stock surge by an astonishing 1,300%. This remarkable rally has been further bolstered by a significant $181 million investment, underscoring strong investor confidence in the company's therapeutic pipeline. The substantial capital infusion is expected to accelerate clinical development and research efforts, potentially bringing its innovative small-molecule therapies closer to market approval. For investors, this dual validation of strong market performance and external financial backing signals robust growth prospects.
- 2/23/2026NEUTRALMadrigal (MDGL) Q4 2025 Earnings Call Transcript
Madrigal Pharmaceuticals has released the transcript of its fourth-quarter 2025 earnings conference call. While the news itself is informational, the document is a crucial resource for investors. Analysts and shareholders can now scrutinize the management's detailed commentary on financial performance, drug pipeline progress, and the strategic outlook for the future. The question-and-answer session will be of particular interest, as it often reveals nuances and details not found in official press releases. The availability of this comprehensive documentation allows for a deeper analysis, but does not in itself provide a directional signal until its contents are fully digested by the market.
via Markets Gazette